The BET Bromodomain Inhibitor (BETi) OTX015 (MK-8628) Upregulates miR-96-5p in Diffuse Large B-Cell Lymphomas (DLBCL)

Aberrant changes in microRNAs (miRNAs), contribute to lymphomagenesis and represent potential therapeutic targets. OTX015 (MK-8628) has demonstrated preclinical and clinical activity in haematological tumours. To better understand the mechanism of action of OTX015 we studied its effects on miRNAs in lymphomas.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Afua Mensah, Luciano Cascione, Eugenio Gaudio, Elena Bernasconi, Chiara Tarantelli, Andrea Rinaldi, Riccardo Bomben, Valter Gattei, Anastasios Stathis, Emanuele Zucca, Ivo Kwee, Francesco Bertoni Source Type: research